Itradora SB 130 Capsule contains Itraconazole 130 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. This disruption results in increased membrane permeability and ultimately fungal cell death. Itradora SB 130 is commonly prescribed for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and candidiasis. The capsule formulation ensures optimal bioavailability and patient compliance. It is important to administer Itradora SB 130 with food to enhance absorption. Dosage and duration depend on the type and severity of infection and should be determined by a healthcare professional. Caution is advised in patients with hepatic impairment, congestive heart failure, or those receiving concomitant medications metabolized by the cytochrome P450 system due to potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Itradora SB 130 Capsule should be used under strict medical supervision to ensure efficacy and safety.